drugset

drugset / Trial / NCT00795574

Study to Assess the Safety and Efficacy of Infliximab to Treat Hidradenitis Suppurtativa

NCT00795574 ↗

Phase 2 Completed 38 enrolled Florida Academic Dermatology Centers

RandomizedCrossoverQuadruple-blindTreatment

Summary

A study to assess the safety and efficacy of the IV drug infliximab for the treatment of hidradenitis suppurativa

Timeline

Start: 2005-06
Primary completion: 2008-08
Completion: 2008-08

Publications

Grant A, Gonzalez T, Montgomery MO, Cardenas V, Kerdel FA. Infliximab therapy for patients with moderate to severe hidradenitis suppurativa: a randomized, double-blind, placebo-controlled crossover trial. J Am Acad Dermatol. 2010 Feb;62(2):205-17. doi: 10.1016/j.jaad.2009.06.050.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Infliximab	Monoclonal antibody	5 mg/kg	Intravenous

Indications